Edition:
India

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

118.05USD
2:29am IST
Change (% chg)

$-1.24 (-1.04%)
Prev Close
$119.29
Open
$119.93
Day's High
$120.41
Day's Low
$115.57
Volume
243,823
Avg. Vol
254,546
52-wk High
$134.51
52-wk Low
$65.81

Select another date:

Wed, Feb 26 2020

BRIEF-Alnylam Announces Approval In Brazil Of Onpattro

* ALNYLAM ANNOUNCES APPROVAL IN BRAZIL OF ONPATTRO® FOR THE TREATMENT OF HEREDITARY ATTR AMYLOIDOSIS WITH POLYNEUROPATHY

Alnylam gene-silencing therapy to treat kidney disorder succeeds in late-stage study

Alnylam Pharmaceuticals Inc's gene-silencing therapy for a rare kidney disorder met the main goal of a late-stage study on Tuesday, bringing the company a step closer to marketing the first approved treatment for the condition.

Alnylam gene-silencing therapy to treat kidney disorder succeeds in late-stage study

Dec 17 Alnylam Pharmaceuticals Inc's gene-silencing therapy for a rare kidney disorder met the main goal of a late-stage study on Tuesday, bringing the company a step closer to marketing the first approved treatment for the condition.

Alnylam's rare genetic disorder drug priced at $575,000 per year

Alnylam Pharmaceuticals Inc priced its gene silencing drug to treat patients with a rare genetic disorder that can cause severe pain at $575,000 per year after receiving an early U.S. approval on Wednesday.

UPDATE 2-Alnylam's rare genetic disorder drug priced at $575,000 per year

Nov 20 Alnylam Pharmaceuticals Inc priced its gene silencing drug to treat patients with a rare genetic disorder that can cause severe pain at $575,000 per year after receiving an early U.S. approval on Wednesday.

U.S. FDA approves Alnylam's drug for rare genetic disorder

Nov 20 The U.S. Food and Drug Administration said on Wednesday it had approved Alnylam Pharmaceuticals Inc's gene silencing drug as a treatment for patients with a rare inherited disorder.

Select another date: